Evicenter
MarkdownMedical informationP&T meetings
Lanifibranor (IVA337)

Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis

Manufacturer
Inventiva
Last updated
220 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis

Humanistic burden and health-related quality of life

15 evidence topics · 14 sources

SF-36 physical and mental health by fibrosis stage in 713 adults with NAFLD, NASH Clinical Research Network
Fatigue and pruritus in 1,669 adults with NASH and bridging fibrosis or compensated cirrhosis, STELLAR 3 and 4 baseline

“were assessed at baseline in patients with histologically confirmed bridging fibrosis (F3) or compensated cirrhosis (F4) due to NASH enrolled in STELLAR 3 and 4.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Among the included 1,669 patients with advanced NASH (mean age = 58 ± 9 years, 48% F3, 42% with psychiatric comorbidities), 33% and 27% had fatigue and pruritus, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“All PRO scores of patients with fatigue were significantly impaired (mean up to −31% of a PRO range size in comparison to patients without fatigue).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“All PROs were impaired (by up to −19% of a range size, all P < 0.01) in patients with NASH with pruritus.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The median pruritus score was 6 (interquartile range [IQR] 4‐7) and did not differ between patients with bridging fibrosis and compensated cirrhosis (P = 0.55).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Although patients with bridging fibrosis had higher median fatigue scores (indicative of less fatigue) than those with cirrhosis (5.0 [IQR 4.0‐5.8] vs. 4.7 [3.5‐5.7]; P = 0.0028), the difference does not meet the threshold of a minimal clinically important difference for domain scores of the CLDQ‐NASH (approximately 0.5 points).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Patient-reported outcomes and fibrosis improvement in 392 adults with NASH and bridging fibrosis or compensated cirrhosis, phase 2 trial NCT03449446

“Patients with NASH with bridging fibrosis or compensated cirrhosis were enrolled in a phase 2, randomized, placebo‐controlled study of selonsertib, firsocostat, or cilofexor, alone or in two‐drug combinations (NCT03449446).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A total of 392 patients with NASH (mean ± SD, 60 ± 9 years old; 35% men; 89% white; 72% diabetes; and 56% compensated cirrhosis) were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Baseline Physical Functioning (PF) and Bodily Pain of SF‐36 and Fatigue and Worry of CLDQ‐NASH were significantly lower in patients with cirrhosis (total CLDQ‐NASH score mean ± SD, 4.91 ± 1.06 with cirrhosis vs. 5.16 ± 1.14 without cirrhosis; P < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“After 48 weeks of treatment, patients with ≥1‐stage fibrosis improvement without worsening of NASH experienced improvement in EQ‐5D and five out of six CLDQ‐NASH domains (P < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Fibrosis regression was independently associated with greater improvements in PF and EQ‐5D scores, while NAS improvement was associated with improvement in fatigue and pruritus (all P < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

CLDQ-MASH domain scores by histologic fibrosis stage (F3 to F4 versus F0 to F2) in adults with MASH
EQ-5D and CLDQ-NAFLD index by early (F0 to F2) and advanced (F3 to F4) fibrosis in adults with NASH, United States and five European countries, GAIN study
Baseline mapped EQ-5D utility by fibrosis stage in 800 adults with biopsy-confirmed MASH and F2 or F3 fibrosis, ESSENCE trial part 1
Baseline groupBaseline EQ-5D utility, mean (SD)
Fibrosis stage 2, semaglutide (n = 169)“0.783 (0.186)”View highlighted excerpt for this quote
Fibrosis stage 2, placebo (n = 81)“0.789 (0.190)”View highlighted excerpt for this quote
Fibrosis stage 3, semaglutide (n = 365)“0.792 (0.176)”View highlighted excerpt for this quote
Fibrosis stage 3, placebo (n = 185)“0.769 (0.194)”View highlighted excerpt for this quote